CliffBio
small molecule

CARBOPLATIN

CARBOPLATIN

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameCARBOPLATIN
Active ingredientCARBOPLATIN
Strength50MG/VIAL
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalJanuary 2006
Marketing statusDISCN

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

CARBOPLATIN patent cliff — loss of exclusivity — | CliffBio